SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI.X is trending as the community anticipates potential exchange listings and discusses its position as a leading meme coin on the Base network. Bullish sentiment is fueled by mentions of possible partnerships and the expectation of significant gains, though some traders advise caution and profit-taking. The coin's performance is being closely watched in relation to broader market trends and potential rate cuts.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid speculation about potential government contracts, fueled by recent institutional buying and a Congress member's disclosed stock purchase. The community is actively discussing the possibility of a short squeeze, citing high short interest and heavy call option flow. BBAI's association with AI and government contracts, especially in defense, remains a key talking point.

Shineco, Inc. is a holding company, which through its subsidiaries, engages in the production and distribution of plant-based products. It operates through the following segments: Rapid Diagnostic and Other, Other Agricultural, and Healthy Meals Products. The Rapid Diagnostic and Other Products segment is conducted through Biowin, which specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases. The Other Agricultural Products segment is conducted through Wintus, which specializes in producing, processing and distribution of agricultural products, such as silk and silk fabrics as well as trading of fresh fruit. The Healthy Meals Products segment is conducted through Fuzhou Meida, which specializes in developing healthy meals for people with slow metabolic health and those in recovery from metabolic disorders. The company was founded on August 20, 1997 and is headquartered in Beijing, China.

Shineco Inc

SISI is trending as traders discuss its potential, referencing 

Presidio Property Trust, Inc. is a self-managed real estate investment trust, which invests in a diverse multi-tenant portfolio of real estate assets. It operates through the following segments: Office and Industrial Properties, Model Home Properties, and Retail Properties. The Office and Industrial Properties segment consists of office buildings and an industrial property leased to a variety of tenants ranging from small businesses to large public companies. The Model Home Properties segment consists of model home residential properties leased to homebuilders. The Retail Properties segment includes shopping centers. The company was founded by Jack Kendrick Heilbron on September 28, 1999 and is headquartered in San Diego, CA.

Presidio Property Trust Inc - Ordinary Shares - Class A

Fueled by a low float and a prior reverse split, $SQFT is experiencing significant volatility and trending upwards, leading to discussions around short squeezes and potential price targets. Community members are actively debating whether the surge is sustainable or a pump and dump, with some pointing to a recent offering and others emphasizing technical indicators. The stock's unusual price action is attracting both bullish and bearish sentiment, with traders closely monitoring key levels for potential breakouts or pullbacks.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MLGO is trending as traders discuss its potential for a short squeeze and compare it to other recently volatile stocks. Community members are debating its valuation, potential for high percentage gains, and upcoming financial reports. Some investors are closely monitoring the stock's price action and volume, anticipating a significant move.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart ($UPST) is trending as the community anticipates benefits from potential rate cuts, which could significantly boost the AI-driven lending platform's financials and expansion. Community members are actively discussing potential price targets and entry points based on Elliott Wave analysis and technical indicators, while also noting the stock's sensitivity to credit market conditions and FOMC announcements. Despite some volatility and short-term pullbacks, many see $UPST as a strong long-term play, especially compared to peers like $AFRM.

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks ($DNA) is trending amid discussions around potential catalysts, including biosecurity initiatives and partnerships with pharmaceutical giants like Eli Lilly and Novo Nordisk, aimed at boosting production and developing new therapies. Community members are actively debating the company's long-term strategy, insider trading activity, and potential for a short squeeze, influenced by reports on institutional ownership and AI-driven advancements. The stock is further influenced by broader market trends, such as potential shifts in US-China relations and regulatory changes impacting the biotech sector.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending due to a repeat $35 million purchase order for its SiCore batteries from a leading UAS manufacturer, signaling growing demand in the drone sector. Community discussions highlight the company's best-in-class battery technology already in production, potential for further upside, and comparisons to competitors like $ENVX. Bullish sentiment also revolves around domestic battery production and potential benefits from tax credits, as well as possible partnerships within the drone industry.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors digest news around updated COVID-19 vaccine approvals and evolving guidance, with some community members expressing concerns about the long-term impact of vaccine liabilities and calling for strategic shifts, including M&A activity. Discussions also revolve around the company's pipeline beyond COVID-19 and the potential for a rotation into value stocks. Some traders are highlighting technical indicators and options activity to inform their strategies.

Dogelon Mars

Dogelon Mars ($ELON.X) is trending as the community discusses its potential, while some express frustration with its performance and unfulfilled promises, including the "Great Burn." Community members are weighing in on whether it's a worthwhile investment amid the broader meme coin landscape and Bitcoin's movements, with some looking for a breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bristol Myers Squibbs Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for...

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2025. The company will participate in a fireside chat at the TD Cowen...

U.S. Food and Drug Administration Accepts Bristol Myers Squibbs Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

U.S. Food and Drug Administration Accepts Bristol Myers Squibbs Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite...

Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo (nivolumab) in combination with...

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb (NYSE:BMY) today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with...

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected...

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell...

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2024. We made good progress in 2024, which was capped by a fourth quarter of strong topline growth...

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab...

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene...

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Celgene Corp.

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

CELG
Celgene Corporation

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CELG News

CELG Celgene Corporation